Heidi Allen, Irina Alexander, Vilmarie Fraguada Narloch, Heather Spiegel
As interest in group psychedelic-assisted therapy grows, researchers are exploring diverse protocols, populations, and psychedelic medicines to enhance therapeutic outcomes and accessibility. This panel brings together experts conducting groundbreaking studies on group-based psychedelic therapy, offering insights into how different approaches can foster healing, connection, and transformation.
Chris Stauffer, Jae Sevelius, Anthony Back
Richard Zeifman, Gabrielle Agin-Liebes
Joseph McCowan, Mia Sarno, Psy.D., Jessica Punzo
Chandra Khalifian, Anne Wagner, Ph.D., Kayla Knopp, Susan McBride
Patil Armenian, Benjamin Hatten
Tadeusz Hawrot, Oksana Gryshchenko, Zina Besirevic, Elise Wilson
Since Australia legalized regulated psychedelic-assisted therapy in 2023, The Psychedelic Consultancy has supported psychiatrists becoming Authorised Prescribers. This presentation reviews early lessons, challenges, and risk management in this psychiatrist-led model.
Chris Raine
MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.
Keren Tzarfaty, Michael Mithoefer, Julie Holland
